Genomic & Biopharma News

New guidelines proposed to deal with in-flight cardiac arrest emergency
New guidelines to deal with the in-flight emergency of cardiac arrest in a passenger or crew member are being proposed at this year's Euroanaesthesia meeting in Geneva.
News Medical Life Sciences, 2017-06-05 08:07:42

Study finds steady decline in severe health problems for childhood cancer survivors
Treatments for childhood cancer are often intense and carry the risk of lifelong health problems for survivors. An analysis of 23,600 childhood cancer survivors in the Childhood Cancer Survivor Study (CCSS), funded by the National Institutes of Health, found that the rate of severe health problems occurring five or more years after diagnosis has declined over time.
News Medical Life Sciences, 2017-06-05 08:04:21

Dova and Novartis-backed Aileron file for new IPOs as biotech offerings tick up
After a poor 2016 and a slow start to 2017, biotech IPOs have started to pick up in recent months and now two upstarts are looking to make their offering.
Fierce Biotech, 2017-06-05 07:59:39

CDC warning on Salmonella infections in humans from backyard poultry
CDC and other U.S health services are investigating eight multistate outbreaks of human Salmonella infections linked to contact with poultry living in the backyards.
News Medical Life Sciences, 2017-06-05 07:47:00

Brief psychological intervention reduces depressive symptoms in patients with advanced cancer
Advanced cancer triggers enormous distress and brings challenges that can seem overwhelming. Yet, most cancer centers lack systematic approaches to help patients and families manage the practical and emotional toll of advanced cancer.
News Medical Life Sciences, 2017-06-05 07:47:00

New targeted oral therapy results in durable responses across many kinds of cancer
Scientists may have developed the first targeted, oral, tumor-type agnostic therapy - a cancer medicine that works comparably well across many kinds of cancer, regardless of patient age. In clinical trials of adults and children with 17 different types of advanced cancer, larotrectinib treatment resulted in responses in 76% of patients.
News Medical Life Sciences, 2017-06-05 07:40:12

Pfizer's two-time loser dacomitinib finally wins in phase 3 against AstraZeneca's Iressa
Pfizer’s EGFR lung cancer candidate, dacomitinib, doesn’t have a pretty past. But the New York drugmaker has finally rung up a phase 3 victory.
Fierce Pharma, 2017-06-05 07:35:48

Vapor from novel hybrid tobacco heating product produces little or no effect on human cells
New laboratory data reveal that vapor from a novel hybrid tobacco heating product (THP) iFuse and two standard THPs produced little or no effect on human cells in biological testing.
News Medical Life Sciences, 2017-06-05 07:30:22

Positive results for AstraZeneca’s PARP inhibitor Lynparza in advanced breast cancer
A new study has shown that AstraZeneca's Lynparza (olaparib) can significantly slow the progress of breast cancer that is caused partially due to mutations of the culprit gene called BRCA. BRCA gene mutations are responsible for around 3% of all breast cancers. These cases of the disease that have a basis in the gene are notoriously difficult to treat and women who are tested positive for this gene may even opt for removal of their breasts before even the cancer strikes. Noted actress Angelina Jolie went for a similar prophylactic mastectomy.
News Medical Life Sciences, 2017-06-05 07:28:24